AbbVie Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (90)

Latest Posts

About This Stock More About This Stock
AbbVie (ABBV) Q3 Earnings Top, Revenues In Line, View Up
Article By: Zacks Investment Research
Friday, October 27, 2017 2:18 PM EST
AbbVie Inc. reported mixed results in the third quarter of 2017. The company surpassed earnings estimates, while posted in-line revenues during the period.
In this article: ABBV Also: JNJ, LLY, AMGN
Read
Baby DivHut Dividend Income Portfolio Update Q3 2017
Article By: Keith Park
Monday, October 23, 2017 1:00 PM EST
With nine months of the year already behind us, I highlight baby DivHut’s quarterly dividend income/portfolio progress. With the stock market continuing to chug along it was nice to see some impressive gains made in the two-year-old portfolio.
In this article: ABT, CAT, EMR, GIS, ITW, JNJ, MMM, PFE, PG, UL, VFC, YUM, ABBV, YUMC
Read
Here's What's Has Happened In The HCV Space Lately
Article By: Zacks Investment Research
Sunday, October 8, 2017 6:08 PM EST
It is not a surprise that quite a few pharma and biotech companies are working on bringing new, improved, shorter-duration hepatitis C virus (HCV) treatments to the market. The market is thus getting crowded and seeing increased pricing pressure.
In this article: JNJ, GILD, ABBV, MRK Also: BMY
Read
XBI Breaks Through On A Strong Week For Biotech
Article By: Rod Raynovich
Friday, September 29, 2017 7:25 PM EST
The XBI is up 3.17% this week, 46% YTD, compared to only 1.1% WTD for the IBB. The breakthrough gains for the XBI can be attributed to strong performance of top ten holdings that are primarily mid-caps and M&A prospects.
In this article: BMY, ALNY, BMRN, IBB, AMGN, CELG, CLVS, XBI, JUNO, PBYI, SRPT, BLUE, PTCT, ABBV, FMI
Read
Biopharmaceuticals Portfolio In A Biotech Bull Market
Article By: Rod Raynovich
Tuesday, September 5, 2017 11:08 PM EST
Biotech stocks broke through the July sector highs as tracked by major ETFs. However we are still about 25% off the July 2015 bubble highs but supported by good earnings fundamentals, strong technicals and potentially a seasonal strong Q4.
In this article: BMY, RHHBY, IBB, QQQ, AMGN, BIIB, GILD, XBI, ABBV, KITE, BLUE, FMI
Read

PARTNER HEADLINES

Latest Tweets for $ABBV

No tweets yet!

$ABBV

AbbVie Inc. Increases Humira Prices, Receives FDA Approval For New Drug
Bruce Powers 1/23/2017 6:21:09 PM

Excited to hear the #FDA approved #IMBRUVICA. Should bode very well for $ABBV. And I think it's 8% price hike of #Humira is reasonable (though I realize those taking the drug may disagree).

1 to 1 of 1 comments